Researchers have discovered an interaction between two molecules may contribute to the development of acute myeloid leukemia. They suggest the pathway could be a potential target for treating the aggressive blood cancer and that one of the molecules could serve as a biomarker in personalized therapy of the disease.
The American Society of Clinical Oncology (ASCO) for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.